Key taskforce rejects rollout of new COVID-19 drug

Interim results from the– uploaded as a pre-print in May but not yet published in a peer-reviewed scientific journal – appear to show dramatic benefits.

The trial gave the drug to 291 patients and compared them to 292 patients given a placebo. The patients were selected as being at high risk of serious COVID-19: they were aged over 55, or had diabetes, obesity, kidney disease, heart failure or asthma.In the placebo group, 21 patients ended up seriously ill; only three of those treated with Sotrovimab did.

If the drug became widely available, people with risk factors could be offered the treatment when they tested positive, he said, which would potentially significantly reduce the number of lives lost to COVID-19. “If it works as well as the clinical trial suggests it should, then absolutely.” Liam Mannix’s Examine newsletter explains and analyses science with a rigorous focus on the evidence.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Key taskforce rejects rollout of new COVID-19 drugA national taskforce says it cannot yet support the use of new treatment Sotrovimab, of which the federal government recently bought more than 7700 doses | liammannix liammannix A national taskforce? .. of people already in the pockets of WHO, WEF, UN, GAVI, Gates, etc? Who's represented in the taskforce? liammannix Whaaat? This government, going in on a drug early that's yet to be approved? I thought their MO was to wait until it's approved, at which point, take a spot at the end of the queue. liammannix Funny all of the vaccines are not FDA approved but being forced on people, though HCQ and Ivermectin vitamin D and Zinc been around for decades and not allowed. what's happening here
Source: smh - 🏆 6. / 80 Read more »